

## NCCN Esophageal and Esophagogastric Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><b>ESOPH-E</b>  <b>Internal request:</b>                      Panel member comment requesting that the panel review/revise regimens listed in the Principles of Systemic Therapy pages.</p>	<p>Based on panel discussion and data in the noted references, the panel consensus was to update and revise the regimens in the Principles of Systemic Therapy pages (ESOPH-E). The revisions to ESOPH-E are as follows:</p> <p><b><u>Preoperative Chemoradiation:</u></b></p> <ul style="list-style-type: none"> <li>• Paclitaxel and carboplatin (category 1)</li> <li>• Cisplatin and fluoropyrimidine (5-FU or capecitabine) (category 1)</li> <li>• Oxaliplatin and fluoropyrimidine (5-FU or capecitabine)</li> <li>• Paclitaxel and cisplatin</li> <li>• Carboplatin and 5-FU (category 2B)</li> <li>• Irinotecan and cisplatin (category 2B)</li> <li>• Docetaxel or paclitaxel and fluoropyrimidine (5-FU or capecitabine) (category 2B)</li> <li>• Oxaliplatin, docetaxel, and capecitabine (category 2B)</li> </ul> <p><b><u>Perioperative Chemotherapy (3 cycles preoperative and 3 cycles postoperative)</u></b>  <b>(Only for adenocarcinoma of the distal esophagus or esophagogastric junction):</b></p> <ul style="list-style-type: none"> <li>• ECF (epirubicin, cisplatin and 5-FU) (category 1)</li> <li>• ECF modifications (category 1)</li> </ul>	<p>See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Esophageal and Esophagogastric Cancers.  <a href="http://www.nccn.org">www.nccn.org</a></p>	22	0	0

## NCCN Esophageal and Esophagogastric Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>ESOPH-E</b> <b>Internal request</b> <b>(Continued from</b> <b>Page 1)</b>	<p><b>Continued from Page 1:</b></p> <p><b><u>Sequential Chemotherapy and Chemoradiation</u></b></p> <ul style="list-style-type: none"> <li>• Irinotecan and cisplatin</li> <li>• Paclitaxel and cisplatin</li> <li>• Docetaxel and cisplatin</li> <li>• 5-fluorouracil and cisplatin; 5-fluorouracil and paclitaxel</li> </ul> <p><b><u>Definitive Chemoradiation:</u></b></p> <ul style="list-style-type: none"> <li>• Cisplatin and fluoropyrimidine (5-FU or capecitabine) (category 1)</li> <li>• Oxaliplatin and fluoropyrimidine (5-FU or capecitabine)</li> <li>• Paclitaxel or docetaxel and cisplatin</li> <li>• Paclitaxel and carboplatin (category 2B)</li> <li>• Irinotecan and cisplatin (category 2B)</li> <li>• Docetaxel or paclitaxel and fluoropyrimidine (5-FU or capecitabine) (category 2B)</li> <li>• Oxaliplatin, docetaxel, and capecitabine (category 2B)</li> </ul> <p><b><u>Postoperative Chemoradiation:</u></b>                      (Only for adenocarcinoma)</p> <ul style="list-style-type: none"> <li>• 5-FU (bolus) and leucovorin (category 1)</li> <li>• LV5FU2 before and after infusion 5-FU or capecitabine with radiation (preferred)</li> </ul>	See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Esophageal and Esophagogastric Cancers. <a href="http://www.nccn.org">www.nccn.org</a>	22	0	0

## NCCN Esophageal and Esophagogastric Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>ESOPH-E</b> <b>Internal request</b> <b>(Continued from page 2)</b>	<p><b><u>Continued from Page 2:</u></b>  <b>Definitive Chemotherapy for Metastatic or Locally Advanced Cancer</b>  <b>[where chemoradiation is not indicated]</b>  <b><u>First-Line Therapy</u></b></p> <ul style="list-style-type: none"> <li>• Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)</li> <li>• DCF (docetaxel, cisplatin and 5-FU) (category 1)</li> <li>• DCF modifications (preferred over DCF) (category 2A; category 2B for docetaxel, carboplatin, and 5-FU)</li> <li>• ECF (category 1)</li> <li>• ECF modifications (category 1)</li> <li>• Fluoropyrimidine (5-FU or capecitabine) and cisplatin</li> <li>• (category 1)</li> <li>• Fluoropyrimidine (5-FU or capecitabine) and oxaliplatin</li> <li>• 5-FU and irinotecan</li> <li>• Paclitaxel with cisplatin or carboplatin</li> <li>• Docetaxel with cisplatin</li> <li>• Docetaxel and irinotecan (category 2B)</li> <li>• Fluoropyrimidine (5-FU or capecitabine)</li> <li>• Docetaxel or paclitaxel</li> </ul>	<p>See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Esophageal and Esophagogastric Cancers.  <a href="http://www.nccn.org">www.nccn.org</a></p>	22	0	0

## NCCN Esophageal and Esophagogastric Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>ESOPH-E</b> <b>Internal request</b> <b>(Continued from page 3)</b>	<p><b><u>Continued from Page 3:</u></b>  <b>Definitive Chemotherapy for Metastatic or Locally Advanced Cancer</b>  <b>[where chemoradiation is not indicated]</b>  <b><u>Second-Line Therapy</u></b>  <b>Dependent on prior therapy and performance status (PS):</b></p> <ul style="list-style-type: none"> <li>• Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma if not used in first-line therapy (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)</li> <li>• Irinotecan and cisplatin</li> <li>• Irinotecan and fluoropyrimidine (5-FU or capecitabine) (category 2B)</li> <li>• Irinotecan and docetaxel (category 2B)</li> <li>• Irinotecan and mitomycin (category 2B)</li> <li>• Docetaxel or paclitaxel (category 2B)</li> <li>• Irinotecan (category 2B)</li> </ul> <p><b><u>Alternative regimens to be considered (these may be combined with other regimens when appropriate) (category 2B):</u></b></p> <ul style="list-style-type: none"> <li>• Gemcitabine, 5-FU, and leucovorin</li> <li>• Pegylated liposomal doxorubicin, cisplatin, and 5-FU</li> <li>• Mitomycin and irinotecan</li> <li>• Mitomycin, cisplatin, and 5-FU</li> <li>• Mitomycin and 5-FU</li> <li>• Etoposide</li> <li>• Erlotinib</li> <li>• Cetuximab</li> </ul>	<p>See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Esophageal and Esophagogastric Cancers.  <a href="http://www.nccn.org">www.nccn.org</a></p>	22	0	0

## NCCN Gastric Cancer Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><b>GAST-E</b>  <b>Internal request:</b>                      Panel member comment requesting that the panel review/revise regimens listed in the Principles of Systemic Therapy pages.</p>	<p>Based on panel discussion and data in the noted references, the panel consensus was to update and revise the regimens in the Principles of Systemic Therapy pages (GAST-E). The revisions to GAST-E are as follows:</p> <p><b><u>Preoperative Chemoradiation (EG junction and gastric cardia):</u></b></p> <ul style="list-style-type: none"> <li>• Paclitaxel and carboplatin (category 1)</li> <li>• Cisplatin and fluoropyrimidine (5-FU or capecitabine) (category 1)</li> <li>• Oxaliplatin and fluoropyrimidine (5-FU or capecitabine)</li> <li>• Paclitaxel and cisplatin</li> <li>• Carboplatin and 5-FU (category 2B)</li> <li>• Irinotecan and cisplatin (category 2B)</li> <li>• Docetaxel or paclitaxel and fluoropyrimidine (5-FU or capecitabine) (category 2B)</li> <li>• Oxaliplatin, docetaxel, and capecitabine (category 2B)</li> </ul> <p><b><u>Perioperative Chemotherapy (including EG junction) (3 cycles preoperative and 3 cycles postoperative):</u></b></p> <ul style="list-style-type: none"> <li>• ECF (epirubicin, cisplatin and 5-FU) (category 1)</li> <li>• ECF modifications (category 1)</li> </ul>	<p>See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Gastric Cancer. (<a href="http://www.nccn.org">www.nccn.org</a>)</p>	22	0	0

## NCCN Gastric Cancer Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>GAST-E</b> <b>Internal request</b> <b>(Continued from</b> <b>Page 1)</b>	<p><b>Continued from Page 1:</b></p> <p><b><u>Sequential Chemotherapy and Chemoradiation</u></b></p> <ul style="list-style-type: none"> <li>• Irinotecan and cisplatin</li> <li>• Paclitaxel and cisplatin</li> <li>• Docetaxel and cisplatin</li> <li>• 5-fluorouracil and cisplatin; 5-fluorouracil and paclitaxel</li> </ul> <p><b><u>Postoperative Chemoradiation (including EG junction):</u></b></p> <ul style="list-style-type: none"> <li>• 5-FU (bolus) and leucovorin (category 1)</li> <li>• LV5FU2 before and after infusion 5-FU or capecitabine with radiation (preferred)</li> </ul>	See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Gastric Cancer. ( <a href="http://www.nccn.org">www.nccn.org</a> )	22	0	0

## NCCN Gastric Cancer Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>GAST-E</b> <b>Internal request</b> <b>(Continued from page 2)</b>	<p><b><u>Continued from Page 2:</u></b>  <b>Definitive Chemotherapy for Metastatic or Locally Advanced Cancer [where chemoradiation is not indicated]</b>  <b><u>First-Line Therapy</u></b></p> <ul style="list-style-type: none"> <li>• Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)</li> <li>• DCF (docetaxel, cisplatin and 5-FU) (category 1)</li> <li>• DCF modifications (preferred over DCF) (category 2A; category 2B for docetaxel, carboplatin, and 5-FU)</li> <li>• ECF (category 1)</li> <li>• ECF modifications (category 1)</li> <li>• Fluoropyrimidine (5-FU or capecitabine) and cisplatin</li> <li>• (category 1)</li> <li>• Fluoropyrimidine (5-FU or capecitabine) and oxaliplatin</li> <li>• 5-FU and irinotecan</li> <li>• Paclitaxel with cisplatin or carboplatin</li> <li>• Docetaxel with cisplatin</li> <li>• Docetaxel and irinotecan (category 2B)</li> <li>• Fluoropyrimidine (5-FU or capecitabine)</li> <li>• Docetaxel or paclitaxel</li> </ul>	<p>See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Gastric Cancer. (<a href="http://www.nccn.org">www.nccn.org</a>)</p>	22	0	0

## NCCN Gastric Cancer Guidelines V.2.2011 – Update Meeting – 09/15/10

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<b>GAST-E</b> <b>Internal request</b> <b>(Continued from page 3)</b>	<p><b><u>Continued from Page 3:</u></b>  <b>Definitive Chemotherapy for Metastatic or Locally Advanced Cancer</b>  <b>[where chemoradiation is not indicated]</b>  <b><u>Second-Line Therapy</u></b>  <b>Dependent on prior therapy and performance status (PS):</b></p> <ul style="list-style-type: none"> <li>• Trastuzumab with chemotherapy for HER2-neu overexpressing adenocarcinoma if not used in first-line therapy (category 1 for combination with cisplatin and fluoropyrimidine; category 2B for combination with other chemotherapy agents; not recommended for use with anthracyclines)</li> <li>• Irinotecan and cisplatin</li> <li>• Irinotecan and fluoropyrimidine (5-FU or capecitabine) (category 2B)</li> <li>• Irinotecan and docetaxel (category 2B)</li> <li>• Irinotecan and mitomycin (category 2B)</li> <li>• Docetaxel or paclitaxel (category 2B)</li> <li>• Irinotecan (category 2B)</li> </ul> <p><b><u>Alternative regimens to be considered (these may be combined with other regimens when appropriate) (category 2B):</u></b></p> <ul style="list-style-type: none"> <li>• Gemcitabine, 5-FU, and leucovorin</li> <li>• Pegylated liposomal doxorubicin, cisplatin, and 5-FU</li> <li>• Mitomycin and irinotecan</li> <li>• Mitomycin, cisplatin, and 5-FU</li> <li>• Mitomycin and 5-FU</li> <li>• Etoposide</li> <li>• Erlotinib</li> <li>• Cetuximab</li> </ul>	See the “Principles of Systemic Therapy” pages in the NCCN Guidelines™ for Gastric Cancer. ( <a href="http://www.nccn.org">www.nccn.org</a> )	22	0	0